175 related articles for article (PubMed ID: 37534375)
1. Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression.
Schafer CC; Jiang J; Elsamanoudi S; Nousome D; Young DY; Song Y; Sesterhenn IA; Chesnut GT; Tan SH
Cancer Res Commun; 2023 Aug; 3(8):1423-1434. PubMed ID: 37534375
[TBL] [Abstract][Full Text] [Related]
2. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.
Cullen J; Young D; Chen Y; Degon M; Farrell J; Sedarsky J; Baptiste W; Rosen P; Tolstikov V; Kiebish M; Kagan J; Srivastava S; Kuo HC; Moncur JT; Rosner IL; Narain N; Akmaev V; Petrovics G; Dobi A; McLeod DG; Srivastava S; Sesterhenn IA
Eur Urol Focus; 2018 Dec; 4(6):818-824. PubMed ID: 28753864
[TBL] [Abstract][Full Text] [Related]
3. High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes.
Hempel Sullivan H; Heaphy CM; Kulac I; Cuka N; Lu J; Barber JR; De Marzo AM; Lotan TL; Joshu CE; Sfanos KS
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):668-675. PubMed ID: 31932412
[TBL] [Abstract][Full Text] [Related]
4. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
[TBL] [Abstract][Full Text] [Related]
5. SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.
Faisal FA; Kaur HB; Tosoian JJ; Tomlins SA; Schaeffer EM; Lotan TL
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):552-559. PubMed ID: 30850708
[TBL] [Abstract][Full Text] [Related]
6. Race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990-2017.
Oehrlein N; Streicher SA; Kuo HC; Chaurasia A; McFadden J; Nousome D; Chen Y; Stroup SP; Musser J; Brand T; Porter C; Rosner IL; Chesnut GT; Onofaro KC; Rebbeck TR; D'Amico A; Lu-Yao G; Cullen J
Cancer Med; 2022 Nov; 11(22):4354-4365. PubMed ID: 35638719
[TBL] [Abstract][Full Text] [Related]
7. Race, tumor location, and disease progression among low-risk prostate cancer patients.
Mygatt JG; Cullen J; Streicher SA; Kuo HC; Chen Y; Young D; Gesztes W; Williams G; Conti G; Porter C; Stroup SP; Rice KR; Rosner IL; Burke A; Sesterhenn I
Cancer Med; 2020 Mar; 9(6):2235-2242. PubMed ID: 31965751
[TBL] [Abstract][Full Text] [Related]
8. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
9. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
10. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.
Yamoah K; Deville C; Vapiwala N; Spangler E; Zeigler-Johnson CM; Malkowicz B; Lee DI; Kattan M; Dicker AP; Rebbeck TR
Urol Oncol; 2015 Feb; 33(2):70.e15-22. PubMed ID: 25304288
[TBL] [Abstract][Full Text] [Related]
11. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
[TBL] [Abstract][Full Text] [Related]
12. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
[TBL] [Abstract][Full Text] [Related]
13. High intratumoral CD8
Yang Y; Attwood K; Bshara W; Mohler JL; Guru K; Xu B; Kalinski P; Chatta G
Prostate; 2021 Jan; 81(1):20-28. PubMed ID: 33085799
[TBL] [Abstract][Full Text] [Related]
14. Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes.
Hempel Sullivan H; Maynard JP; Heaphy CM; Lu J; De Marzo AM; Lotan TL; Joshu CE; Sfanos KS
J Pathol; 2021 Apr; 253(4):415-426. PubMed ID: 33338262
[TBL] [Abstract][Full Text] [Related]
15. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Fuletra JG; Kamenko A; Ramsey F; Eun DD; Reese AC
Can J Urol; 2018 Feb; 25(1):9193-9198. PubMed ID: 29524974
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
[TBL] [Abstract][Full Text] [Related]
17. Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry.
Aminsharifi A; Polascik TJ; Tsivian M; Schulman A; Tsivian E; Tay KJ; Elshafei A; Jones JS
Clin Genitourin Cancer; 2018 Oct; 16(5):e1073-e1076. PubMed ID: 30054221
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
Bissonette EA; Fulmer BR; Petroni GR; Moul JW; Theodorescu D
J Urol; 2001 Oct; 166(4):1328-31; discussion 1331-2. PubMed ID: 11547067
[TBL] [Abstract][Full Text] [Related]
19. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
[TBL] [Abstract][Full Text] [Related]
20. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde E; Alkallas R; Chua MLK; Fraser M; Haider S; Meng A; Zheng J; Yao CQ; Picard V; Orain M; Hovington H; Murgic J; Berlin A; Lacombe L; Bergeron A; Fradet Y; Têtu B; Lindberg J; Egevad L; Grönberg H; Ross-Adams H; Lamb AD; Halim S; Dunning MJ; Neal DE; Pintilie M; van der Kwast T; Bristow RG; Boutros PC
Eur Urol; 2017 Jul; 72(1):22-31. PubMed ID: 27815082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]